CA2659558A1 - Pack containing pharmaceutical administration forms - Google Patents
Pack containing pharmaceutical administration forms Download PDFInfo
- Publication number
- CA2659558A1 CA2659558A1 CA 2659558 CA2659558A CA2659558A1 CA 2659558 A1 CA2659558 A1 CA 2659558A1 CA 2659558 CA2659558 CA 2659558 CA 2659558 A CA2659558 A CA 2659558A CA 2659558 A1 CA2659558 A1 CA 2659558A1
- Authority
- CA
- Canada
- Prior art keywords
- pack
- container
- pharmaceutical administration
- pack according
- blister pack
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000007787 solid Substances 0.000 claims abstract description 41
- 239000002250 absorbent Substances 0.000 claims description 27
- 239000002274 desiccant Substances 0.000 claims description 27
- 230000002745 absorbent Effects 0.000 claims description 26
- -1 polypropylene Polymers 0.000 claims description 22
- 239000004800 polyvinyl chloride Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 18
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 17
- 239000004743 Polypropylene Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 229920001155 polypropylene Polymers 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 claims description 11
- 229920001903 high density polyethylene Polymers 0.000 claims description 10
- 239000004700 high-density polyethylene Substances 0.000 claims description 10
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 10
- 239000005033 polyvinylidene chloride Substances 0.000 claims description 10
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 claims description 9
- 239000002131 composite material Substances 0.000 claims description 8
- 229920001328 Polyvinylidene chloride Polymers 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 5
- 239000008298 dragée Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000002808 molecular sieve Substances 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical group [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 241001484259 Lacuna Species 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 1
- 150000001925 cycloalkenes Chemical class 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 abstract description 12
- 239000002985 plastic film Substances 0.000 description 38
- 239000011888 foil Substances 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 230000035699 permeability Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003856 thermoforming Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000004308 accommodation Effects 0.000 description 4
- 239000001913 cellulose Chemical class 0.000 description 4
- 229920002678 cellulose Chemical class 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007942 layered tablet Substances 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920004439 Aclar® Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000005030 aluminium foil Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000009516 primary packaging Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000009517 secondary packaging Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Chemical class OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Chemical class 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229920002774 Maltodextrin Chemical class 0.000 description 1
- 239000005913 Maltodextrin Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Chemical class 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical class OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Chemical class 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical class O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012536 packaging technology Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229920013744 specialty plastic Polymers 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D77/00—Packages formed by enclosing articles or materials in preformed containers, e.g. boxes, cartons, sacks or bags
- B65D77/04—Articles or materials enclosed in two or more containers disposed one within another
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/04—Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, or spherical or like small articles, e.g. tablets or pills
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/04—Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, or spherical or like small articles, e.g. tablets or pills
- B65D83/0445—Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, or spherical or like small articles, e.g. tablets or pills all the articles being stored in individual compartments
- B65D83/0463—Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, or spherical or like small articles, e.g. tablets or pills all the articles being stored in individual compartments formed in a band or a blisterweb, inserted in a dispensing device or container
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Food Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Composite Materials (AREA)
- Packages (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a packaging comprising solid pharmaceutical forms packed into a container (2) and in blisters (4).
Description
Pack containing pharmaceutical administration forms The invention relates to a pack comprising a container and solid pharma-ceutical administration forms packed in blister packs, and to a method for the stabilisation of solid pharmaceutical administration forms by introduction of the solid pharmaceutical administration forms into blister packs and introduction of the blister packs into the container.
Blister packs below are taken to mean packaging comprising two sheets, films or foils which are firmly bonded to one another and which contain cavities for the accommodation of the solids to be packed. Blister packs usually consist of a thermoformed plastic sheet or film (cavity sheet or film) for the accommodation of the solids, which, after filling, is firmly bonded, i.e.
heat-sealed, to a second sheet, film or foil (cover sheet, film or foil), which usually consists of an aluminium foil and/or plastic sheet or film. The pack-aged solids can be pushed through the cover sheet, film or foil by pressure on the cavity sheet, film or foil and removed individually from the blister pack. Blister packs are therefore also known as push-through packs. If "pushing-through" the cover sheet, film or foil is not possible owing to the shape, size and/or strength of the solids contained, the blister packs can also be opened by slitting open the cover sheet, film or foil using a sharp object, for example using the finger nail. However, the term "blister pack" is not restricted thereto, but also encompasses special embodiments, such as, for example, child-proof modifications, such as, for example, those in which it is necessary to carry out two different opening operations whose sequences are intended to be beyond the intellectual capacity of children (such as so-called "peel-push systems"), or embodiments in which the cover sheet, film or foil is not punctured, but instead peeled off before removal of the solids contained.
Blister packs are the preferred primary packaging means for solid pharma-ceutical administration forms. Advantages are that the administration forms can be removed individually and thus without contamination of the other administration forms, which are furthermore contained in sealed cavities, the administration forms are separated from one another (meaning that mutual interaction, such as, for example, abrasion or sticking, are basically prevented).
A further important function of blister packs is protection of the pharmaceu-tical administration forms contained therein against harmful environmental influences, such as light, gases, in particular oxygen, and against moisture.
The last-mentioned function in particular is of particular importance since many medicaments are sensitive to moisture. Since blister packs are usu-ally accommodated in folding cartons, which are not effective barriers against moisture and gases, the crucial protective action in the case of solid pharmaceutical administration forms packaged in blister packs (primary packaging means) and folding cartons (secondary packaging means) arises through the blister packs.
However, the plastic sheets or films used for blister packs only provide lim-ited protection against gases and moisture ingressing from the outside.
Various plastic sheets or films, such as, for example, polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), high-density polyethylene (HDPE), polypropylene (PP), polyethylene terephthalate (PET), polycarbonate, each of which have different material properties, stand. Although the selection of a material of relatively low permeability for moisture or the use of composite sheets or films made from these materials, such as, for example, PVC/PVDC, PVC/HDPE, optionally also together with further polymers as barrier layer, such as, for example, cycloolefin copolymer (COC), or special polyhalogenated polymers, such as polychlorotrifluoroethylene (PCTFE) Aclar , (PVC/ PCTFE, PP/COC (for example Polybar ) PVC/COC/PVDC
composite sheets or films), enables the ingress of moisture to be reduced to a certain degree, it does not prevent it completely.
Besides the choice of plastic, the material thickness, i.e. the sheet, film or foil thickness, also has an essential influence on the permeability of the blister pack. Thus, besides the selection of the materials and the combina-tion thereof to give composite sheets or films, the permeability for gases and moisture can also be reduced by increasing the sheet, film or foil thick-ness. However, even these measures have only a limited effect and in addition do not result in the desired substantial exclusion of moisture.
Higher production complexity, greater use of materials and difficulties in converting the sheets, films or foils into blisters packs and recycling thereof also arise disadvantageously.
The use of composite sheets or films which also comprise metal foils enables the permeabiiity for moisture and gases to be significantly reduced again, but in this case particular difficulties arise during processing (ther-moforming). On use of composite sheets or films comprising metal foils, the blister packs are also no longer transparent, meaning that the customer can no longer see the pharmaceutical administration forms contained therein, which is undesired for security and marketing reasons.
The problems described have the consequence that many moisture-sensi-tive medicaments are not packed in blister packs for export and marketing in regions of increased atmospheric humidity, for example in the tropics.
In order to solve the problems described, special blister packs have been proposed which contain desiccants and consequently are intended to keep the moisture away from the medicament.
EP 466068 discloses a blister pack in which in each case a tablet cavity is connected to a cavity containing a desiccant. However, the provision of a desiccant per administration form, such as, for example, a tablet, is associ-ated with high material consumption and space occupancy, is complex in terms of packaging technology and is expensive.
US 4753352 discloses a blister pack in which a plurality of tablet cavities are connected to a cavity containing a desiccant. Although this enables the packaging complexity per pharmaceutical administration form to be reduced, the removal of only one pharmaceutical administration form from the blister pack results in opening of the previously closed system, with the consequence that moisture is able to ingress through the resultant opening.
After exhaustion of the moisture uptake of the desiccant connected thereto, the other pharmaceutical administration forms connected to this desiccant are then no longer adequately protected against ingressing moisture by the sheet or film and by the desiccant connection channels. Furthermore, it cannot be excluded in either system that the desiccant is removed and ingested instead of the pharmaceutical administration form, which is ex-tremely serious for safety reasons.
Regarding the last-mentioned problem of unintentional ingestion, EP 779872 Al proposes a reinforcement of the blister packs in the region of the desiccant cavities, which is intended to prevent unintentional inges-tion of the desiccant by the user. However, this results in an additional increase in the production complexity and cost, which are increased any-way due to the introduction of desiccant.
Whereas simple blister packs often provide only inadequate protection against moisture, the desiccant-containing blister packs have a complex structure, are difficult and therefore expensive to manufacture, cannot be manufactured in production facilities for simple blister packs, take up more space owing to the desiccant contained and thus increase the storage space requirement, and/or are afflicted with safety problems. Furthermore, adequate protection against moisture likewise cannot always be ensured with desiccant-containing blister packs.
The object of the present invention was to provide simple packaging for pharmaceutical administration forms in which the pharmaceutical admini-stration forms are present in separated form, in which reliable protection against moisture is ensured and which is not afflicted with the above-men-tioned problems.
Blister packs below are taken to mean packaging comprising two sheets, films or foils which are firmly bonded to one another and which contain cavities for the accommodation of the solids to be packed. Blister packs usually consist of a thermoformed plastic sheet or film (cavity sheet or film) for the accommodation of the solids, which, after filling, is firmly bonded, i.e.
heat-sealed, to a second sheet, film or foil (cover sheet, film or foil), which usually consists of an aluminium foil and/or plastic sheet or film. The pack-aged solids can be pushed through the cover sheet, film or foil by pressure on the cavity sheet, film or foil and removed individually from the blister pack. Blister packs are therefore also known as push-through packs. If "pushing-through" the cover sheet, film or foil is not possible owing to the shape, size and/or strength of the solids contained, the blister packs can also be opened by slitting open the cover sheet, film or foil using a sharp object, for example using the finger nail. However, the term "blister pack" is not restricted thereto, but also encompasses special embodiments, such as, for example, child-proof modifications, such as, for example, those in which it is necessary to carry out two different opening operations whose sequences are intended to be beyond the intellectual capacity of children (such as so-called "peel-push systems"), or embodiments in which the cover sheet, film or foil is not punctured, but instead peeled off before removal of the solids contained.
Blister packs are the preferred primary packaging means for solid pharma-ceutical administration forms. Advantages are that the administration forms can be removed individually and thus without contamination of the other administration forms, which are furthermore contained in sealed cavities, the administration forms are separated from one another (meaning that mutual interaction, such as, for example, abrasion or sticking, are basically prevented).
A further important function of blister packs is protection of the pharmaceu-tical administration forms contained therein against harmful environmental influences, such as light, gases, in particular oxygen, and against moisture.
The last-mentioned function in particular is of particular importance since many medicaments are sensitive to moisture. Since blister packs are usu-ally accommodated in folding cartons, which are not effective barriers against moisture and gases, the crucial protective action in the case of solid pharmaceutical administration forms packaged in blister packs (primary packaging means) and folding cartons (secondary packaging means) arises through the blister packs.
However, the plastic sheets or films used for blister packs only provide lim-ited protection against gases and moisture ingressing from the outside.
Various plastic sheets or films, such as, for example, polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), high-density polyethylene (HDPE), polypropylene (PP), polyethylene terephthalate (PET), polycarbonate, each of which have different material properties, stand. Although the selection of a material of relatively low permeability for moisture or the use of composite sheets or films made from these materials, such as, for example, PVC/PVDC, PVC/HDPE, optionally also together with further polymers as barrier layer, such as, for example, cycloolefin copolymer (COC), or special polyhalogenated polymers, such as polychlorotrifluoroethylene (PCTFE) Aclar , (PVC/ PCTFE, PP/COC (for example Polybar ) PVC/COC/PVDC
composite sheets or films), enables the ingress of moisture to be reduced to a certain degree, it does not prevent it completely.
Besides the choice of plastic, the material thickness, i.e. the sheet, film or foil thickness, also has an essential influence on the permeability of the blister pack. Thus, besides the selection of the materials and the combina-tion thereof to give composite sheets or films, the permeability for gases and moisture can also be reduced by increasing the sheet, film or foil thick-ness. However, even these measures have only a limited effect and in addition do not result in the desired substantial exclusion of moisture.
Higher production complexity, greater use of materials and difficulties in converting the sheets, films or foils into blisters packs and recycling thereof also arise disadvantageously.
The use of composite sheets or films which also comprise metal foils enables the permeabiiity for moisture and gases to be significantly reduced again, but in this case particular difficulties arise during processing (ther-moforming). On use of composite sheets or films comprising metal foils, the blister packs are also no longer transparent, meaning that the customer can no longer see the pharmaceutical administration forms contained therein, which is undesired for security and marketing reasons.
The problems described have the consequence that many moisture-sensi-tive medicaments are not packed in blister packs for export and marketing in regions of increased atmospheric humidity, for example in the tropics.
In order to solve the problems described, special blister packs have been proposed which contain desiccants and consequently are intended to keep the moisture away from the medicament.
EP 466068 discloses a blister pack in which in each case a tablet cavity is connected to a cavity containing a desiccant. However, the provision of a desiccant per administration form, such as, for example, a tablet, is associ-ated with high material consumption and space occupancy, is complex in terms of packaging technology and is expensive.
US 4753352 discloses a blister pack in which a plurality of tablet cavities are connected to a cavity containing a desiccant. Although this enables the packaging complexity per pharmaceutical administration form to be reduced, the removal of only one pharmaceutical administration form from the blister pack results in opening of the previously closed system, with the consequence that moisture is able to ingress through the resultant opening.
After exhaustion of the moisture uptake of the desiccant connected thereto, the other pharmaceutical administration forms connected to this desiccant are then no longer adequately protected against ingressing moisture by the sheet or film and by the desiccant connection channels. Furthermore, it cannot be excluded in either system that the desiccant is removed and ingested instead of the pharmaceutical administration form, which is ex-tremely serious for safety reasons.
Regarding the last-mentioned problem of unintentional ingestion, EP 779872 Al proposes a reinforcement of the blister packs in the region of the desiccant cavities, which is intended to prevent unintentional inges-tion of the desiccant by the user. However, this results in an additional increase in the production complexity and cost, which are increased any-way due to the introduction of desiccant.
Whereas simple blister packs often provide only inadequate protection against moisture, the desiccant-containing blister packs have a complex structure, are difficult and therefore expensive to manufacture, cannot be manufactured in production facilities for simple blister packs, take up more space owing to the desiccant contained and thus increase the storage space requirement, and/or are afflicted with safety problems. Furthermore, adequate protection against moisture likewise cannot always be ensured with desiccant-containing blister packs.
The object of the present invention was to provide simple packaging for pharmaceutical administration forms in which the pharmaceutical admini-stration forms are present in separated form, in which reliable protection against moisture is ensured and which is not afflicted with the above-men-tioned problems.
The object has, surprisingly, been achieved by firstly introducing the phar-maceutical administration forms into a simple blister pack and subsequently introducing the latter into a container in whose inside wall(s) at least one channel former is embedded together with at least one absorbent, at least over part of the area, and tightly sealed. The invention thus relates to a pack comprising a resealable container in whose inside wall(s) at least one channel former is embedded together with at least one absorbent, at least over part of the area, and at least one blister pack containing one or more solid pharmaceutical administration forms, where the blister pack(s) is (are) contained in the container.
The container is intended for the storage of at least one blister pack. It can therefore have any spatial shapes which fulfil this function, i.e. those which are suitable for accommodating at least one blister pack. It is preferred for the spatial shape of the container to be matched to the dimensions of the blister pack. If it is intended, for example, to store blister packs having a rectangular shape, it is preferred for the container to have the same basic shape, i.e.
for the container to have the spatial shape of a cuboid, if it is intended to store blister packs having a circular shape, it is preferred for the container to have the spatial shape of a cylinder. However, it is likewise possible in accordance with the invention to employ as container any desired spatial shape irrespec-tive of the shape of the blister pack, so long merely that it is suitable for accommodating the blister pack. For example, a blister pack having a circular shape can also be stored in a container having a cuboid spatial shape or a blister pack having a rectangular shape can also be stored in a container having a cylindrical spatial shape.
Individual embodiments of the invention are depicted in the figures. Uniform numbering is used to denote the constituents of the embodiments shown in the figures, i.e. identical numbers in the figures in each case denote the same constituents.
The container is intended for the storage of at least one blister pack. It can therefore have any spatial shapes which fulfil this function, i.e. those which are suitable for accommodating at least one blister pack. It is preferred for the spatial shape of the container to be matched to the dimensions of the blister pack. If it is intended, for example, to store blister packs having a rectangular shape, it is preferred for the container to have the same basic shape, i.e.
for the container to have the spatial shape of a cuboid, if it is intended to store blister packs having a circular shape, it is preferred for the container to have the spatial shape of a cylinder. However, it is likewise possible in accordance with the invention to employ as container any desired spatial shape irrespec-tive of the shape of the blister pack, so long merely that it is suitable for accommodating the blister pack. For example, a blister pack having a circular shape can also be stored in a container having a cuboid spatial shape or a blister pack having a rectangular shape can also be stored in a container having a cylindrical spatial shape.
Individual embodiments of the invention are depicted in the figures. Uniform numbering is used to denote the constituents of the embodiments shown in the figures, i.e. identical numbers in the figures in each case denote the same constituents.
Figure 1 shows a cuboid container containing a blister pack having a rectan-gular shape. The container comprises walls (2) whose inward-facing sides comprise at least one channel former together with at least one absorbent, at least over part of the area, has as closure a lid (1) and is provided with an (optional) opening aid (3). The blister pack (4) contains cavities (5) for the accommodation of the solid pharmaceutical administration forms.
Figure 2 shows, like Figure 1, a cuboid container and a blister pack, but with different dimensions of the container and a blister pack having a circular shape.
Figure 3 shows a container having a cylindrical spatial shape. The round wall (2) comprises at least one channel former together with at least one absorbent in the inward-facing side, at least over part of the area and is provided with a fitting circular lid (1) and (optional) filling aid (3). The blister pack (4) has a strip-shaped design, contains oval cavities (5) for the accommodation of the solid administration forms and is provided with a tear-off aid (6) along which the blisters can be divided.
The container is resealable. Resealable means that the container can be opened and re-closed repeatedly, i.e. at least once, preferably a number of times, particularly preferably at least as often as corresponds to the number of solid pharmaceutical administration forms which, packed in blister packs, are intended to be contained in the container. The container is tightly sealed after each opening and sealing operation so that ingress of moisture and gases into the interior of the container is effectively prevented.
Opening and sealing of the container are effected by means of a tightly clos-ing closure matched to the container. Not restricted to one closure. All types of closures can be employed so long as they ensure that gases and/or moisture cannot ingress into the interior of the container in the closed state even after repeated opening and closing of the container. The container can have one or more closures. In the case of cuboid containers, each of the rectangular sur-faces can basically be designed as a closure. Figure 4 shows an embodiment of a cuboid container having two closures (1).
According to an embodiment of the invention, lids (1) are used as closure.
Examples of lids are screw closures, caps which are folded over the upper rim of the vessels or introduced into the interior of the vessel. In the case of spa-tial shapes which have corners, such as, for example, cuboids, the corners of the opening and the lid fitted thereto may also be slightly rounded in order to increase the sealing of the container against gases and moisture.
According to a preferred embodiment, the container has a cuboid spatial shape, rounded corners (7) and can be stacked well (see Figure 5).
The absorbents and channel formers contained in the container may jointly either be present directly in the inside wall(s) of the polymer forming the con-tainer or applied as a layer to the inside wall(s) of the polymeric container.
Absorbents and channel formers may likewise be embedded in an inlay, which is introduced into the container as insert, so that at least part of the inside walls of the container are lined therewith.
Inside wall(s) is taken to mean the inward-facing surface of the wall(s) of the container, i.e. the surface(s) of the container which is (are) in contact with the solid pharmaceutical administration forms contained therein packed in blister packs.
Suitable materials for the container are polymers. Polymers which can be em-ployed as a mixture with absorbents and channel formers are, in particular, thermoplastics, such as, for example, polyolefins, such as polyethylene and/or polypropylenes, polyisoprenes, polybutadienes, polybutenes, polysiloxanes, polyamides, ethylene-vinyl acetate copolymers, ethylene-methacrylate co-polymers, polystyrenes, polyesters, polyanhydrides, polyacrylate nitriles, poly-sulfonates, polyester-amides, polyacrylate esters, propylene-maleic anhydride, polyethylene-maleic anhydride, polyethylene-urethanes, polyethylene-ethyl vinyl alcohols, polyethylene-nylon and/or polyurethanes. The walls provided on their inside surface with absorbents and channel formers have, based on the total weight of the mixture of polymer, channel formers and absorbents, a polymer content of 10 - 90% by weight.
Absorbents which may be present are in principle any type of desiccants, i.e.
moisture-binding binders. Three groups of desiccants come into consideration:
The first group includes chemical substances which form hydrates with water. Examples of chemical substances of this type are anhydrous salts, which tend to absorb water or moisture and in the process form a stable hydrate. The moisture is bound and liberation thereof is prevented by a chemical reaction.
The second group of desiccants contains substances which are reactive.
The substances react with water or moisture by forming a new substance.
The newly formed substances are normally stable at low temperatures, which is only reversible with expenditure of high energy. Desiccants of this type are principally used for drying solvents and as water-absorbent mate-rial in the case of polymers which themselves have to remain in a reduced-moisture state.
The third group of desiccants binds the moisture by physical adsorption.
The desiccant contains particles having fine capillaries into which the moisture is drawn. The pore size of the capillaries and the density thereof in the desiccant determine the absorption properties. Examples of desiccants of this type are molecular sieves, silica gels, certain synthetic polymers, such as, for example, those which are used in nappies, and starches. Des-iccants from the third group are preferably contained in the container since they are substantially inert and water-insoluble. Particular preference is given here to molecular sieves having a pore size of 3 to 15 Angstrom and/or silica gels having a pore size of 24 Angstrom.
Channel formers which come into consideration are hydrophilic substances, such as, for example, polyglycols, ethyl vinyl alcoles, glycerol, polyvinyl alco-hols, polyvinylpyrrolidone, vinylpyrrolidone, N-methylpyrrolidone, polysaccha-rides, saccharides and/or sugar alcohols. Preferred polyglycols are polyethyl-ene glycol and/or polypropylene glycol. Saccharides which can be used are, for example, glucose, mannose, galactose and/or fructose. Suitable sugar alcohols are, for example, mannitol, sorbitol, hexitol, dulcitol, xylitol, ribitol and/or erythrol. Polysaccharides are taken to mean, for example, dextrins and/or hydrolysed starch.
In the inside walls provided with absorbents and channel formers, the channel formers can have a proportion of 10 - 40% by weight, based on the total weight of the mixture of polymer, channel formers and absorbents.
Absorbents and channel formers are embedded in the inside wall(s) of the container over part of the area or over the entire area. Over part of the area means that at least part of the entire area of the container forming the inside wall(s) comprises absorbents and channel formers. Over the entire area means that the entire area of the container forming the inside walls comprises absorbents and channel formers. According to an advantageous embodiment, absorbents and channel formers are present in at least 10%, preferably in at least 50%, particularly preferably in at least 90%, of the inside walls, based on the entire inside surface area of the container.
Containers made from polymers which comprise absorbents and channel formers and which are suitable as container for the pack according to the invention are known in the prior art and are described, for example, in WO 97/32663 Al, EP 1000873 A2 and WO 03/086900 Al, EP 1421991 Al. Containers which can be employed in the pack according to the inven-tion are commercially available and are offered, for example, by Capitol Specialty Plastics Inc., 2039 McMillan Street Auburn, Alabama, USA, under the trade name Activ-Vial, or by Sud Chemie, Ostenrieder Str. 15, 85368 Moosburg, Germany, under the trade name 2 AP Multipolymer.
The blister packs can preferably and advantageously be made from simple plastic sheets or films which have high permeability for water vapour. After introduction of the blister pack into the container and sealing thereof, they are then located in a dry environment, which is ensured by the drying effect of the absorbent located in the walls of the container. In the case of a rela-tively high moisture content in the interiors of the blister packs (containing the solid pharmaceutical administration forms) compared with the interior of the container (which is ensured by the desiccant), this diffuses through the plastic sheet or film of the blister packs into the interior of the container, where it is absorbed by the desiccant present in the container walls. If the pharmaceutical administration forms contained in the blisters have a higher moisture content than the interiors of the blisters surrounding them, moisture diffuses out of the pharmaceutical administration forms into the interiors of the blisters and then further, as described, through the plastic sheet or film of the blister packs into the interior of the container. In the case of an increased moisture content of the pharmaceutical administration forms compared with the interior of the container, drying of the solid pharmaceutical administration forms thus occurs even after packaging thereof.
Compared with commercially available blister packs packaged in folding cartons, a reversal of the diffusion direction of moisture, which generally takes place from the outside inward, i.e. in the direction of the pharmaceuti-cal administration form, in conventional secondary packaging for blister packs, such as folding cartons, in the direction from the inside outward, i.e.
out of the cavity of the blister pack and also out of the pharmaceutical administration form, occures in the pack according to the invention. Drying of the pharmaceutical administration form consequently arises for the pack according to the invention even after manufacture and packaging of the pharmaceutical administration forms in blister packs, which advantageously results in a further increase in the shelf life, in particular in the case of pharmaceutical administration forms having sensitive ingredients.
Owing to the drying which takes place in the pack according to the invention after the pharmaceutical administration forms have been dispensed into the blister packs, the pharmaceutical administration forms can also be provided less expensively since drying times necessary after their manufacture can be omitted or shortened.
Suitable for use for the manufacture of blister packs which are suitable for the pack according to the invention are all plastic sheets or films which can be converted into blister packs in corresponding plants, in particular thermoforming plants, and which have a certain water-vapour permeability.
Examples of plastic sheets and films which are suitable for the manufacture of blister packs are polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), high-density polyethylene (HDPE), polypropylene (PP), polyethyl-ene terephthalate (PET), polycarbonate, cycloolefin copolymer (COC), spe-cial polyhalogenated polymers, such as polychlorotrifluoroethylene (PCTFE) Aclar , and composite sheets or films made from these materials, such as, for example, PVC/PVDC, PVC/HDPE, PVC/PCTFE, PP/COC
(Polybar ) PVC/COC/PVDC, particularly suitable are PVC, PVDC, HDPE, PP, PET and composite sheets or films made from these, very particularly suitable PVC, PP, and PET. The plastic sheets or films can be employed as cavity sheet or film and/or as cover sheet or film. The cavity sheet or film at least preferably consists of a plastic sheet or film.
Plastic sheets or films of low thickness are preferably and advantageously employed for the manufacture of the blister packs. This is because a reduc-tion in the material thickness of the sheets or films is also accompanied by a reduction in the diffusion resistance thereof, so that the described stabili-sation of the pharmaceutical administration form can occur even more quickly due to removal of moisture during storage. The plastic sheets or films used as cavity sheet or film usually have a thickness of 10 to 500 pm, preferably 15 to 300 pm, particularly preferably 15 to 100 pm, very particu-larly preferably 15 to 50.
High permeability for water vapour and low sheet or film thickness enable the use of inexpensive plastic sheets or films, such as, for example, PVC, PP, and PET, which have a water-vapour permeability (WVP) in accor-dance with DIN 53122 of about 3.5, 0.84 and 5.4 g/cm224h respectively at a thickness of 250 pm. Besides savings in material costs, sheets or films of this type can also be processed and filled well in conventional thermoform-ing plants, giving rise to additional cost advantages.
Aluminium foil, which has low water permeability, is usually employed for sealing blister packs. Low water permeability is not necessary in the pack according to the invention, meaning that other materials can also be em-ployed for sealing the blister packs. This enables the use of plastic sheets or films as cover sheet or film, where sheets or films made from the same material as the cavity sheet or film can also be used. Single-material pack-aging of this type is particularly advantageous since it can be recycled with-out prior separation of cavity sheet or film and cover sheet or film, which is particularly desired for environmental protection reasons. On use of plastic sheets or films as cover sheet or film, water vapour present in the cavities of the blister pack can also be removed through the cover sheet or film, which advantageously increases the drying rate of the pharmaceutical administration forms contained in the blister pack. If, in addition, a plastic sheet or film of very low material thickness is used, a further increase in the drying rate and easier removal of the solid pharmaceutical administration form contained in the blister pack arise, since this can be pushed through more easily, besides reduced material usage.
According to an advantageous embodiment, each cavity of the blister pack containing a solid pharmaceutical administration form contains at least one hole. The hole/holes preferably have a diameter of < 1 mm, they simplify the exchange of gases and moisture from the cavities of the blister packs in the interior of the container of the pack according to the invention, meaning that the drying rate is significantly increased. The holes also enable plastic sheets or films of high gas and moisture permeability and increased sheet or film thickness to be used for the blister packs without the stabilisation arising due to the drying being reduced. The invention therefore also relates to the pack according to the invention which is characterised in that the blister pack(s) contained in the pack has at least one hole in each cavity which contains a solid pharmaceutical administration form.
If a plurality of holes are present, they are preferably in the form of a row of small cuts/punched holes, i.e. a perforation, which, inter alia, simplify tear-ing-off along the line forming. The invention therefore also relates to pack which is characterised in that a plurality of holes are present as perforation in each cavity.
The perforations are particularly preferably microperforations, i.e. holes having a respective diameter of between 0.25 and 0.05 mm, which can be punched into the sheets or films. The invention therefore furthermore relates to a pack which is characterised in that the perforation present in each cavity is a microperforation.
The holes/perforations may be present in the cavity sheet or film and/or the cover sheet or film of the blister packs and introduced into the sheets or films either before or after filling of the blisters. The holes/perforations can be introduced by methods known from the prior art, such as, for example, by mechanical punching or by burning-in by means of laser light. The holes/perforations can be introduced into the plastic sheets or films before conversion thereof into blister packs, during conversion thereof into blister packs and also after the manufacture and filling of the blister packs.
If pre-holed/pre-perforated sheets or films are employed, it is preferred for only the cover sheet or film to be holed/perforated. This enables problem-free processing of the cavity sheet or film in conventional thermoforming plants and protects the pharmaceutical administration forms against contamination in the thermoforming plant after introduction thereof into the cavities. The filled cavity sheet or film can subsequently be heat-sealed to the cover sheet or film without problems, the latter preferably being perforated, particularly preferably microperforated. Figure 3 shows a blister pack (4) which is provided with per-forations (8). If the pharmaceutical administration forms are removed by pushing through the cover sheet or film, the perforations are preferably intro-duced in such a way that the cover sheet or film can be torn along the perfora-tions in the case of pressure on the cavity sheet or film and the administration forms can be removed in a simple manner. The invention therefore further-more relates to the pack according to the invention which is characterised in that the hole, holes, perforation or microperforation is (are) in each case introduced in the cover sheet or film.
Pharmaceutical administration forms which can be contained in the pack are all solid pharmaceutical administration forms which are in the solid physical state at room temperature and are intended, for example, for oral, anal or vaginal administration. This encompasses all solid pharmaceutical administration forms which are intended for direct administration after removal from the container, such as, for example, tablets, dragees, hard capsules, granules, pellets, powders, suppositories, but also those which have to be converted into the administrable form before administration, such as, for example, dry juices, for example in the form of powders which have to be converted into solution before administration. The pharmaceuti-cal administration form is preferably a tablet, a dragee, a hard capsule, a granular material, a suppository, a pellet or a powder. Hard capsules have shells without added plasticiser, can be divided into upper and lower part and consist, for example, of gelatine or starch.
The invention also relates to a process for the production of the pack, which is characterised in that the solid pharmaceutical administration forms is introduced into a blister pack and sealed, and the sealed blister pack is subsequently introduced into a container which [lacuna] of a tightly sealable container in whose inside wall(s) at least one channel former is embedded together with at least one absorbent, at least over part of the area.
Pharmaceutical administration form(s) above and below is taken to mean a term for various technical administration forms as are known for the admini-stration of medicaments to humans or animals. The expression pharmaceuti-cal administration form is thus independent of a particular legal status and in no way restricted to medicaments, various substances, such as, for example, medicaments, food supplements and/or functional ingredients, may be pre-sent as ingredients. Examples of pharmaceutical administration forms for the purposes of the present invention can be in the form of medicaments and food supplements.
Surprisingly, the process according to the invention also enables the provi-sion of marketable products of solid pharmaceutical administration forms which were hitherto unsuitable for marketing in accordance with the prior art since they do not have an adequate shelf life. After transfer of the admini-stration form into the container, water is removed continuously and over a long period from the administration form by the absorbent present in the inside wall(s) of the container. The removal of water takes place over a large area and under mild conditions and thus results in stabilisation of the solid pharmaceutical administration form during storage thereof.
The invention therefore also relates to a method for increasing the shelf life of solid pharmaceutical administration forms which is characterised in that the latter is introduced into a blister pack and sealed, and the sealed blister pack is subsequently introduced into a container which consists of a tightly sealable container in whose inside wall(s) at least one channel former is embedded together with at least one absorbent, at least over part of the area.
The stabilising action of the pack according to the invention is based on the influence of the container on the solid pharmaceutical administration form contained in blister packs, which can consequently be provided in a stor-age-stable manner. The achievement of the action according to the inven-tion thus requires that the solid pharmaceutical administration form con-tained in blister packs is contained in the container, i.e. the pharmaceutical administration form, blister pack and container together are in the form of a pack.
Figure 2 shows, like Figure 1, a cuboid container and a blister pack, but with different dimensions of the container and a blister pack having a circular shape.
Figure 3 shows a container having a cylindrical spatial shape. The round wall (2) comprises at least one channel former together with at least one absorbent in the inward-facing side, at least over part of the area and is provided with a fitting circular lid (1) and (optional) filling aid (3). The blister pack (4) has a strip-shaped design, contains oval cavities (5) for the accommodation of the solid administration forms and is provided with a tear-off aid (6) along which the blisters can be divided.
The container is resealable. Resealable means that the container can be opened and re-closed repeatedly, i.e. at least once, preferably a number of times, particularly preferably at least as often as corresponds to the number of solid pharmaceutical administration forms which, packed in blister packs, are intended to be contained in the container. The container is tightly sealed after each opening and sealing operation so that ingress of moisture and gases into the interior of the container is effectively prevented.
Opening and sealing of the container are effected by means of a tightly clos-ing closure matched to the container. Not restricted to one closure. All types of closures can be employed so long as they ensure that gases and/or moisture cannot ingress into the interior of the container in the closed state even after repeated opening and closing of the container. The container can have one or more closures. In the case of cuboid containers, each of the rectangular sur-faces can basically be designed as a closure. Figure 4 shows an embodiment of a cuboid container having two closures (1).
According to an embodiment of the invention, lids (1) are used as closure.
Examples of lids are screw closures, caps which are folded over the upper rim of the vessels or introduced into the interior of the vessel. In the case of spa-tial shapes which have corners, such as, for example, cuboids, the corners of the opening and the lid fitted thereto may also be slightly rounded in order to increase the sealing of the container against gases and moisture.
According to a preferred embodiment, the container has a cuboid spatial shape, rounded corners (7) and can be stacked well (see Figure 5).
The absorbents and channel formers contained in the container may jointly either be present directly in the inside wall(s) of the polymer forming the con-tainer or applied as a layer to the inside wall(s) of the polymeric container.
Absorbents and channel formers may likewise be embedded in an inlay, which is introduced into the container as insert, so that at least part of the inside walls of the container are lined therewith.
Inside wall(s) is taken to mean the inward-facing surface of the wall(s) of the container, i.e. the surface(s) of the container which is (are) in contact with the solid pharmaceutical administration forms contained therein packed in blister packs.
Suitable materials for the container are polymers. Polymers which can be em-ployed as a mixture with absorbents and channel formers are, in particular, thermoplastics, such as, for example, polyolefins, such as polyethylene and/or polypropylenes, polyisoprenes, polybutadienes, polybutenes, polysiloxanes, polyamides, ethylene-vinyl acetate copolymers, ethylene-methacrylate co-polymers, polystyrenes, polyesters, polyanhydrides, polyacrylate nitriles, poly-sulfonates, polyester-amides, polyacrylate esters, propylene-maleic anhydride, polyethylene-maleic anhydride, polyethylene-urethanes, polyethylene-ethyl vinyl alcohols, polyethylene-nylon and/or polyurethanes. The walls provided on their inside surface with absorbents and channel formers have, based on the total weight of the mixture of polymer, channel formers and absorbents, a polymer content of 10 - 90% by weight.
Absorbents which may be present are in principle any type of desiccants, i.e.
moisture-binding binders. Three groups of desiccants come into consideration:
The first group includes chemical substances which form hydrates with water. Examples of chemical substances of this type are anhydrous salts, which tend to absorb water or moisture and in the process form a stable hydrate. The moisture is bound and liberation thereof is prevented by a chemical reaction.
The second group of desiccants contains substances which are reactive.
The substances react with water or moisture by forming a new substance.
The newly formed substances are normally stable at low temperatures, which is only reversible with expenditure of high energy. Desiccants of this type are principally used for drying solvents and as water-absorbent mate-rial in the case of polymers which themselves have to remain in a reduced-moisture state.
The third group of desiccants binds the moisture by physical adsorption.
The desiccant contains particles having fine capillaries into which the moisture is drawn. The pore size of the capillaries and the density thereof in the desiccant determine the absorption properties. Examples of desiccants of this type are molecular sieves, silica gels, certain synthetic polymers, such as, for example, those which are used in nappies, and starches. Des-iccants from the third group are preferably contained in the container since they are substantially inert and water-insoluble. Particular preference is given here to molecular sieves having a pore size of 3 to 15 Angstrom and/or silica gels having a pore size of 24 Angstrom.
Channel formers which come into consideration are hydrophilic substances, such as, for example, polyglycols, ethyl vinyl alcoles, glycerol, polyvinyl alco-hols, polyvinylpyrrolidone, vinylpyrrolidone, N-methylpyrrolidone, polysaccha-rides, saccharides and/or sugar alcohols. Preferred polyglycols are polyethyl-ene glycol and/or polypropylene glycol. Saccharides which can be used are, for example, glucose, mannose, galactose and/or fructose. Suitable sugar alcohols are, for example, mannitol, sorbitol, hexitol, dulcitol, xylitol, ribitol and/or erythrol. Polysaccharides are taken to mean, for example, dextrins and/or hydrolysed starch.
In the inside walls provided with absorbents and channel formers, the channel formers can have a proportion of 10 - 40% by weight, based on the total weight of the mixture of polymer, channel formers and absorbents.
Absorbents and channel formers are embedded in the inside wall(s) of the container over part of the area or over the entire area. Over part of the area means that at least part of the entire area of the container forming the inside wall(s) comprises absorbents and channel formers. Over the entire area means that the entire area of the container forming the inside walls comprises absorbents and channel formers. According to an advantageous embodiment, absorbents and channel formers are present in at least 10%, preferably in at least 50%, particularly preferably in at least 90%, of the inside walls, based on the entire inside surface area of the container.
Containers made from polymers which comprise absorbents and channel formers and which are suitable as container for the pack according to the invention are known in the prior art and are described, for example, in WO 97/32663 Al, EP 1000873 A2 and WO 03/086900 Al, EP 1421991 Al. Containers which can be employed in the pack according to the inven-tion are commercially available and are offered, for example, by Capitol Specialty Plastics Inc., 2039 McMillan Street Auburn, Alabama, USA, under the trade name Activ-Vial, or by Sud Chemie, Ostenrieder Str. 15, 85368 Moosburg, Germany, under the trade name 2 AP Multipolymer.
The blister packs can preferably and advantageously be made from simple plastic sheets or films which have high permeability for water vapour. After introduction of the blister pack into the container and sealing thereof, they are then located in a dry environment, which is ensured by the drying effect of the absorbent located in the walls of the container. In the case of a rela-tively high moisture content in the interiors of the blister packs (containing the solid pharmaceutical administration forms) compared with the interior of the container (which is ensured by the desiccant), this diffuses through the plastic sheet or film of the blister packs into the interior of the container, where it is absorbed by the desiccant present in the container walls. If the pharmaceutical administration forms contained in the blisters have a higher moisture content than the interiors of the blisters surrounding them, moisture diffuses out of the pharmaceutical administration forms into the interiors of the blisters and then further, as described, through the plastic sheet or film of the blister packs into the interior of the container. In the case of an increased moisture content of the pharmaceutical administration forms compared with the interior of the container, drying of the solid pharmaceutical administration forms thus occurs even after packaging thereof.
Compared with commercially available blister packs packaged in folding cartons, a reversal of the diffusion direction of moisture, which generally takes place from the outside inward, i.e. in the direction of the pharmaceuti-cal administration form, in conventional secondary packaging for blister packs, such as folding cartons, in the direction from the inside outward, i.e.
out of the cavity of the blister pack and also out of the pharmaceutical administration form, occures in the pack according to the invention. Drying of the pharmaceutical administration form consequently arises for the pack according to the invention even after manufacture and packaging of the pharmaceutical administration forms in blister packs, which advantageously results in a further increase in the shelf life, in particular in the case of pharmaceutical administration forms having sensitive ingredients.
Owing to the drying which takes place in the pack according to the invention after the pharmaceutical administration forms have been dispensed into the blister packs, the pharmaceutical administration forms can also be provided less expensively since drying times necessary after their manufacture can be omitted or shortened.
Suitable for use for the manufacture of blister packs which are suitable for the pack according to the invention are all plastic sheets or films which can be converted into blister packs in corresponding plants, in particular thermoforming plants, and which have a certain water-vapour permeability.
Examples of plastic sheets and films which are suitable for the manufacture of blister packs are polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), high-density polyethylene (HDPE), polypropylene (PP), polyethyl-ene terephthalate (PET), polycarbonate, cycloolefin copolymer (COC), spe-cial polyhalogenated polymers, such as polychlorotrifluoroethylene (PCTFE) Aclar , and composite sheets or films made from these materials, such as, for example, PVC/PVDC, PVC/HDPE, PVC/PCTFE, PP/COC
(Polybar ) PVC/COC/PVDC, particularly suitable are PVC, PVDC, HDPE, PP, PET and composite sheets or films made from these, very particularly suitable PVC, PP, and PET. The plastic sheets or films can be employed as cavity sheet or film and/or as cover sheet or film. The cavity sheet or film at least preferably consists of a plastic sheet or film.
Plastic sheets or films of low thickness are preferably and advantageously employed for the manufacture of the blister packs. This is because a reduc-tion in the material thickness of the sheets or films is also accompanied by a reduction in the diffusion resistance thereof, so that the described stabili-sation of the pharmaceutical administration form can occur even more quickly due to removal of moisture during storage. The plastic sheets or films used as cavity sheet or film usually have a thickness of 10 to 500 pm, preferably 15 to 300 pm, particularly preferably 15 to 100 pm, very particu-larly preferably 15 to 50.
High permeability for water vapour and low sheet or film thickness enable the use of inexpensive plastic sheets or films, such as, for example, PVC, PP, and PET, which have a water-vapour permeability (WVP) in accor-dance with DIN 53122 of about 3.5, 0.84 and 5.4 g/cm224h respectively at a thickness of 250 pm. Besides savings in material costs, sheets or films of this type can also be processed and filled well in conventional thermoform-ing plants, giving rise to additional cost advantages.
Aluminium foil, which has low water permeability, is usually employed for sealing blister packs. Low water permeability is not necessary in the pack according to the invention, meaning that other materials can also be em-ployed for sealing the blister packs. This enables the use of plastic sheets or films as cover sheet or film, where sheets or films made from the same material as the cavity sheet or film can also be used. Single-material pack-aging of this type is particularly advantageous since it can be recycled with-out prior separation of cavity sheet or film and cover sheet or film, which is particularly desired for environmental protection reasons. On use of plastic sheets or films as cover sheet or film, water vapour present in the cavities of the blister pack can also be removed through the cover sheet or film, which advantageously increases the drying rate of the pharmaceutical administration forms contained in the blister pack. If, in addition, a plastic sheet or film of very low material thickness is used, a further increase in the drying rate and easier removal of the solid pharmaceutical administration form contained in the blister pack arise, since this can be pushed through more easily, besides reduced material usage.
According to an advantageous embodiment, each cavity of the blister pack containing a solid pharmaceutical administration form contains at least one hole. The hole/holes preferably have a diameter of < 1 mm, they simplify the exchange of gases and moisture from the cavities of the blister packs in the interior of the container of the pack according to the invention, meaning that the drying rate is significantly increased. The holes also enable plastic sheets or films of high gas and moisture permeability and increased sheet or film thickness to be used for the blister packs without the stabilisation arising due to the drying being reduced. The invention therefore also relates to the pack according to the invention which is characterised in that the blister pack(s) contained in the pack has at least one hole in each cavity which contains a solid pharmaceutical administration form.
If a plurality of holes are present, they are preferably in the form of a row of small cuts/punched holes, i.e. a perforation, which, inter alia, simplify tear-ing-off along the line forming. The invention therefore also relates to pack which is characterised in that a plurality of holes are present as perforation in each cavity.
The perforations are particularly preferably microperforations, i.e. holes having a respective diameter of between 0.25 and 0.05 mm, which can be punched into the sheets or films. The invention therefore furthermore relates to a pack which is characterised in that the perforation present in each cavity is a microperforation.
The holes/perforations may be present in the cavity sheet or film and/or the cover sheet or film of the blister packs and introduced into the sheets or films either before or after filling of the blisters. The holes/perforations can be introduced by methods known from the prior art, such as, for example, by mechanical punching or by burning-in by means of laser light. The holes/perforations can be introduced into the plastic sheets or films before conversion thereof into blister packs, during conversion thereof into blister packs and also after the manufacture and filling of the blister packs.
If pre-holed/pre-perforated sheets or films are employed, it is preferred for only the cover sheet or film to be holed/perforated. This enables problem-free processing of the cavity sheet or film in conventional thermoforming plants and protects the pharmaceutical administration forms against contamination in the thermoforming plant after introduction thereof into the cavities. The filled cavity sheet or film can subsequently be heat-sealed to the cover sheet or film without problems, the latter preferably being perforated, particularly preferably microperforated. Figure 3 shows a blister pack (4) which is provided with per-forations (8). If the pharmaceutical administration forms are removed by pushing through the cover sheet or film, the perforations are preferably intro-duced in such a way that the cover sheet or film can be torn along the perfora-tions in the case of pressure on the cavity sheet or film and the administration forms can be removed in a simple manner. The invention therefore further-more relates to the pack according to the invention which is characterised in that the hole, holes, perforation or microperforation is (are) in each case introduced in the cover sheet or film.
Pharmaceutical administration forms which can be contained in the pack are all solid pharmaceutical administration forms which are in the solid physical state at room temperature and are intended, for example, for oral, anal or vaginal administration. This encompasses all solid pharmaceutical administration forms which are intended for direct administration after removal from the container, such as, for example, tablets, dragees, hard capsules, granules, pellets, powders, suppositories, but also those which have to be converted into the administrable form before administration, such as, for example, dry juices, for example in the form of powders which have to be converted into solution before administration. The pharmaceuti-cal administration form is preferably a tablet, a dragee, a hard capsule, a granular material, a suppository, a pellet or a powder. Hard capsules have shells without added plasticiser, can be divided into upper and lower part and consist, for example, of gelatine or starch.
The invention also relates to a process for the production of the pack, which is characterised in that the solid pharmaceutical administration forms is introduced into a blister pack and sealed, and the sealed blister pack is subsequently introduced into a container which [lacuna] of a tightly sealable container in whose inside wall(s) at least one channel former is embedded together with at least one absorbent, at least over part of the area.
Pharmaceutical administration form(s) above and below is taken to mean a term for various technical administration forms as are known for the admini-stration of medicaments to humans or animals. The expression pharmaceuti-cal administration form is thus independent of a particular legal status and in no way restricted to medicaments, various substances, such as, for example, medicaments, food supplements and/or functional ingredients, may be pre-sent as ingredients. Examples of pharmaceutical administration forms for the purposes of the present invention can be in the form of medicaments and food supplements.
Surprisingly, the process according to the invention also enables the provi-sion of marketable products of solid pharmaceutical administration forms which were hitherto unsuitable for marketing in accordance with the prior art since they do not have an adequate shelf life. After transfer of the admini-stration form into the container, water is removed continuously and over a long period from the administration form by the absorbent present in the inside wall(s) of the container. The removal of water takes place over a large area and under mild conditions and thus results in stabilisation of the solid pharmaceutical administration form during storage thereof.
The invention therefore also relates to a method for increasing the shelf life of solid pharmaceutical administration forms which is characterised in that the latter is introduced into a blister pack and sealed, and the sealed blister pack is subsequently introduced into a container which consists of a tightly sealable container in whose inside wall(s) at least one channel former is embedded together with at least one absorbent, at least over part of the area.
The stabilising action of the pack according to the invention is based on the influence of the container on the solid pharmaceutical administration form contained in blister packs, which can consequently be provided in a stor-age-stable manner. The achievement of the action according to the inven-tion thus requires that the solid pharmaceutical administration form con-tained in blister packs is contained in the container, i.e. the pharmaceutical administration form, blister pack and container together are in the form of a pack.
The pack according to the invention has a stabilising action on all solid pharmaceutical administration forms whose active compound(s) and/or adjuvant(s) are sensitive to moisture. Examples of moisture-sensitive active compounds are many pharmaceutical active compounds, such as hor-mones or proteins, vitamins, cells, such as, for exampie, probiotic cultures.
The pack according to the invention preferably contains solid pharmaceuti-cal administration forms which comprise moisture-sensitive active com-pounds and/or moisture-sensitive adjuvants or adjuvant combinations. An adjuvant combination which is sensitive to moisture is, for example, the combination of an organic acid, such as, for example, citric acid, with car-bonate, such as, for example, sodium hydrogencarbonate or potassium hydrogencarbonate, as used as in effervescent tablets.
The solid pharmaceutical administration form contained in the pack according to the invention may in addition, depending on the embodiment, comprise conventional adjuvants and additives. The choice of adjuvants and/or additives also depends on the food-law provisions of the country in which the solid pharmaceutical administration form contained in the pack is intended to be used. Adjuvants and/or additives used, for exampie for tab-lets, multilayered tablets, dragees, hard capsules, granules, pellet prepara-tions and/or powders, are starch (for example maize starch), talc, micro-crystalline cellulose, lactose, highly disperse silicon dioxide, polyvinyl-pyrrolidone and/or cellulose powder. Further constituents which may be present as binders and/or release agents are carbohydrates, such as, for example, mannitol, sorbitol, xylitol, glucose, sucrose, fructose, maltose, dextrose, maltodextrin and/or kaolin, and/or cellulose derivatives, such as, for example, methylcellulose, hydroxypropylcellulose and/or hydroxypropyl-methylcellulose, and/or calcium carbonate, calcium stearate, magnesium stearate and/or glycerol stearate. Furthermore, the solid pharmaceutical administration form contained in the pack may also comprise dyes, flavours and/or aromas, as well as lubricants, antioxidants and/or stabilisers. The content of these base substances depends on the one hand on the target content of the substances to be administered, such as medicaments, food supplements, functional ingredients, on the other hand on criteria which determine the mechanical-physical properties of the oral administration form, such as, for example, hardness, compressibility, size, colour and/or shape.
The solid pharmaceutical administration form contained in the pack can also be prepared by various methods known to the person skilled in the art.
These methods are known, for example, from H. Sucker, P. Fuchs, P.
Speiser, "Pharmazeutische Technologie" [Pharmaceutical Technology], Stuttgart 1978 or K.H. Bauer, K.H. Fromming, C. Fuhrer, "Pharmazeutische Technologie" [Pharmaceutical Technology], Stuttgart 1986. They are hereby incorporated as reference and are thus part of the disclosure.
The examples explain the invention without being restricted thereto.
The pack according to the invention preferably contains solid pharmaceuti-cal administration forms which comprise moisture-sensitive active com-pounds and/or moisture-sensitive adjuvants or adjuvant combinations. An adjuvant combination which is sensitive to moisture is, for example, the combination of an organic acid, such as, for example, citric acid, with car-bonate, such as, for example, sodium hydrogencarbonate or potassium hydrogencarbonate, as used as in effervescent tablets.
The solid pharmaceutical administration form contained in the pack according to the invention may in addition, depending on the embodiment, comprise conventional adjuvants and additives. The choice of adjuvants and/or additives also depends on the food-law provisions of the country in which the solid pharmaceutical administration form contained in the pack is intended to be used. Adjuvants and/or additives used, for exampie for tab-lets, multilayered tablets, dragees, hard capsules, granules, pellet prepara-tions and/or powders, are starch (for example maize starch), talc, micro-crystalline cellulose, lactose, highly disperse silicon dioxide, polyvinyl-pyrrolidone and/or cellulose powder. Further constituents which may be present as binders and/or release agents are carbohydrates, such as, for example, mannitol, sorbitol, xylitol, glucose, sucrose, fructose, maltose, dextrose, maltodextrin and/or kaolin, and/or cellulose derivatives, such as, for example, methylcellulose, hydroxypropylcellulose and/or hydroxypropyl-methylcellulose, and/or calcium carbonate, calcium stearate, magnesium stearate and/or glycerol stearate. Furthermore, the solid pharmaceutical administration form contained in the pack may also comprise dyes, flavours and/or aromas, as well as lubricants, antioxidants and/or stabilisers. The content of these base substances depends on the one hand on the target content of the substances to be administered, such as medicaments, food supplements, functional ingredients, on the other hand on criteria which determine the mechanical-physical properties of the oral administration form, such as, for example, hardness, compressibility, size, colour and/or shape.
The solid pharmaceutical administration form contained in the pack can also be prepared by various methods known to the person skilled in the art.
These methods are known, for example, from H. Sucker, P. Fuchs, P.
Speiser, "Pharmazeutische Technologie" [Pharmaceutical Technology], Stuttgart 1978 or K.H. Bauer, K.H. Fromming, C. Fuhrer, "Pharmazeutische Technologie" [Pharmaceutical Technology], Stuttgart 1986. They are hereby incorporated as reference and are thus part of the disclosure.
The examples explain the invention without being restricted thereto.
Example 1:
3-layered tablet analogous to in EP 931 543 Al containing probiotic bacte-ria Manufacture:
Mixtures of 3% by weight of bacteria preparation (containing Lactobacillus gasseri, Bifidobacterium bifidum, Bifidobacterium longum), 10.5% by weight of inulin, 8.6% by weight of calcium phosphate, 5.7% by weight of cellulose, 2.3% by weight of adjuvants (disintegrants, release agents) (1st layer), mineral substances, trace elements, dyes, disintegrants, release agents, cellulose (2nd layer) and vitamins, trace elements, disintegrants, release agents and cellulose (3rd layer) (percentage data in each case based on the total tablet weight) are pressed successively in a 3-layered tablet press (rotary) from E. Hata to give an oblong-shaped 3-layered tablet having the dimensions 18 mm x 8 mm. The tablets obtained are subsequently pro-vided with a film coating (from aqueous solution comprising hydroxypropyl-methylcellulose, hydroxypropyicellulose and a release agent), the coating amounted to 5% by weight, based on the weight of the core, corresponding to 11 mg/cm2 of tablet surface. Coated 3-layered tablets are obtained hav-ing a weight of 1050 mg each.
Storage and testing:
The stability of the film tablets is checked in stability studies. To this end, film tablets are introduced either into PVC/aluminium blister packs (pack-aging means A) or into PVC/aluminium blister packs and the latter are introduced into a packaging means in whose inside wall a channel former is embedded together with an absorbent, (packaging means B). and stored at 40 C/75% RH. After pre-determined times, the tablets are removed from storage, and the microorganism count present in each case is determined by counting by the Koch pour plate method. The results are shown in Table 1 (average of three batches) Test parameter Start Storage condition 40 C/75% RH
13 weeks 26 weeks Packaging means A
Probiotic cultures 7.1 -10' < 1.0-103 -[KBE]
Packaging means B
Probiotic cultures 7.1 .10' 5.5-10' 6.7-10' [KBE]
Table 1 Example 2:
Production:
Mixtures of 10% by weight of nicorandil and adjuvants (fillers, disintegrants and release agents) are pressed in a tablet press to give a round tablet.
Tablets are obtained having a weight of 100 mg each.
3-layered tablet analogous to in EP 931 543 Al containing probiotic bacte-ria Manufacture:
Mixtures of 3% by weight of bacteria preparation (containing Lactobacillus gasseri, Bifidobacterium bifidum, Bifidobacterium longum), 10.5% by weight of inulin, 8.6% by weight of calcium phosphate, 5.7% by weight of cellulose, 2.3% by weight of adjuvants (disintegrants, release agents) (1st layer), mineral substances, trace elements, dyes, disintegrants, release agents, cellulose (2nd layer) and vitamins, trace elements, disintegrants, release agents and cellulose (3rd layer) (percentage data in each case based on the total tablet weight) are pressed successively in a 3-layered tablet press (rotary) from E. Hata to give an oblong-shaped 3-layered tablet having the dimensions 18 mm x 8 mm. The tablets obtained are subsequently pro-vided with a film coating (from aqueous solution comprising hydroxypropyl-methylcellulose, hydroxypropyicellulose and a release agent), the coating amounted to 5% by weight, based on the weight of the core, corresponding to 11 mg/cm2 of tablet surface. Coated 3-layered tablets are obtained hav-ing a weight of 1050 mg each.
Storage and testing:
The stability of the film tablets is checked in stability studies. To this end, film tablets are introduced either into PVC/aluminium blister packs (pack-aging means A) or into PVC/aluminium blister packs and the latter are introduced into a packaging means in whose inside wall a channel former is embedded together with an absorbent, (packaging means B). and stored at 40 C/75% RH. After pre-determined times, the tablets are removed from storage, and the microorganism count present in each case is determined by counting by the Koch pour plate method. The results are shown in Table 1 (average of three batches) Test parameter Start Storage condition 40 C/75% RH
13 weeks 26 weeks Packaging means A
Probiotic cultures 7.1 -10' < 1.0-103 -[KBE]
Packaging means B
Probiotic cultures 7.1 .10' 5.5-10' 6.7-10' [KBE]
Table 1 Example 2:
Production:
Mixtures of 10% by weight of nicorandil and adjuvants (fillers, disintegrants and release agents) are pressed in a tablet press to give a round tablet.
Tablets are obtained having a weight of 100 mg each.
Claims (13)
1. Pack comprising a resealable container in whose inside wall(s) at least one channel former is embedded together with at least one absorbent, at least over part of the area, and at least one blister pack containing one or more solid pharmaceutical administration forms, where the blister pack(s) is (are) contained in the container.
2. Pack according to Claim 1, characterised in that the container has a cuboid basic shape.
3. Pack according to Claim 1 or 2, characterised in that the container contains, as absorbent, a desiccant which binds moisture by physical adsorption.
4. Pack according to Claim 3, characterised in that the desiccant is a molecular sieve or silica gel.
5. Pack according to Claim 1, characterised in that the cavity and/or cover sheet or film of the blister pack(s) contained therein consists of polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), high-density polyethylene (HDPE), polypropylene (PP), polyethylene terephthalate (PET), polycarbonate, cyclo-olefin copolymer (COC), polychlorotrifluoroethylene (PCTFE), or of composite sheets or films made from these materials, such as PVC/PVDC, PVC/HDPE, PVC/PCTFE, PP/COC, PVC/COC/PVDC.
6. Pack according to Claim 5, characterised in that as cavity and/or cover sheet or film consist of PVC, PP or PET.
7. Pack according to Claim 1, characterised in that the blister pack(s) contained in the pack is contain at least one hole in each cavity containing a solid phar-maceutical administration form.
8. Pack according to Claim 7, characterised in that a plurality of holes are pre-sent as perforation in each cavity.
9. Pack according to Claim 8, characterised in that the perforation is a micro-perforation.
10. Pack according to one or more of Claims 7 to 9, characterised in that the hole, holes, perforation or microperforation is (are) in each case introduced in the cover sheet or film.
11. Pack according to Claim 1, characterised in that the solid pharmaceutical administration form(s) contained in the blister pack(s) contained therein are tablets, dragees, capsules, granules, suppositories, pellets and/or powders.
12. Process for the production of the pack according to one or more of Claims 1 to 11, characterised in that the solid pharmaceutical administration forms is introduced into a blister pack and sealed, and the sealed blister pack is sub-sequently introduced into a container which [lacuna] of a tightly sealable con-tainer in whose inside wall(s) at least one channel former is embedded together with at least one absorbent, at least over part of the area.
13. Method for increasing the shelf life of solid pharmaceutical administration forms, characterised in that the latter is introduced into a blister pack and sealed, and the sealed blister pack is subsequently introduced into a container which consists of a tightly sealable container in whose inside wall(s) at least one channel former is embedded together with at least one absorbent, at least over part of the area.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06016222 | 2006-08-03 | ||
EP06016222.9 | 2006-08-03 | ||
PCT/EP2007/005898 WO2008014862A1 (en) | 2006-08-03 | 2007-07-04 | Packaging comprising pharmaceutical forms |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2659558A1 true CA2659558A1 (en) | 2008-02-07 |
Family
ID=38537812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2659558 Abandoned CA2659558A1 (en) | 2006-08-03 | 2007-07-04 | Pack containing pharmaceutical administration forms |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090314664A1 (en) |
EP (1) | EP2046662A1 (en) |
JP (1) | JP2009545343A (en) |
KR (1) | KR20090036606A (en) |
CN (1) | CN101495385A (en) |
AU (1) | AU2007280754B2 (en) |
BR (1) | BRPI0714619A2 (en) |
CA (1) | CA2659558A1 (en) |
MX (1) | MX2009001041A (en) |
RU (1) | RU2448026C2 (en) |
WO (1) | WO2008014862A1 (en) |
ZA (1) | ZA200901464B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2675892A1 (en) * | 2007-01-20 | 2008-07-24 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Pack containing soft capsules |
PT2098249E (en) * | 2008-03-05 | 2013-01-07 | Rivopharm Sa | Nicorandil carriers with enhanced stability |
WO2009117403A1 (en) * | 2008-03-17 | 2009-09-24 | The Procter & Gamble Company | User-customizable dosing system |
WO2009147095A1 (en) * | 2008-06-04 | 2009-12-10 | Boerhringer Ingelheim International Gmbh | Method of drying sheets |
DE102008056123B4 (en) * | 2008-11-06 | 2017-11-16 | Klöckner Pentaplast Gmbh | Multilayer film and blister packaging |
JP5809985B2 (en) | 2009-02-26 | 2015-11-11 | グラクソ グループ リミテッドGlaxo Group Limited | A medicament comprising 4-{(1R) -2-[(6- {2-[(2,6-dichlorobenzyl) oxy] ethoxy} hexyl) amino] -1-hydroxyethyl} -2- (hydroxymethyl) phenol Formulation |
US20110303570A1 (en) * | 2009-03-02 | 2011-12-15 | Astellas Pharma Inc. | Package of solid pharmaceutical preparation |
CN101865595A (en) * | 2009-04-14 | 2010-10-20 | 瑞阳制药有限公司 | New application of molecular sieve and drying method of solid drugs |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
US8479921B2 (en) * | 2009-12-09 | 2013-07-09 | Amcor Flexibles, Inc. | Child resistant blister package |
DK2547308T3 (en) | 2010-03-18 | 2014-11-17 | Medcomb Holding Aps | INSULABLE DISPOSAL CONTAINER FOR PHARMACEUTICAL COMPOSITIONS |
US20110266189A1 (en) * | 2010-05-03 | 2011-11-03 | Tom Nicole L | Blister packaging |
EP2659213A4 (en) * | 2010-09-30 | 2014-10-15 | Richard W Bland | Coal fine drying method and system |
EP2758022B1 (en) | 2011-09-21 | 2015-11-04 | MedComb Holding ApS | A disposable rigid container for pharmaceutical compositions |
US20140264167A1 (en) * | 2013-03-15 | 2014-09-18 | Multisorb Technologies, Inc. | Water vapor barrier composition |
DE14721256T1 (en) * | 2013-04-22 | 2017-03-16 | Sandoz Ag | PHARMACEUTICAL COMPOSITIONS WITH CRYSTALLINE MACITENTANE |
KR102512109B1 (en) | 2015-05-25 | 2023-03-20 | 베베베 게엠베하 | Insertion body, assembly of insertion bodies and method for inserting an insertion body |
JP6927663B2 (en) * | 2015-10-23 | 2021-09-01 | ニプロ株式会社 | Solid preparation package and odor removal method for solid preparation |
KR102503428B1 (en) * | 2015-12-22 | 2023-02-24 | 한미약품 주식회사 | Package for oral soft capsule formulation comprising dutasteride |
EP3568294A4 (en) * | 2017-01-16 | 2020-09-16 | Multisorb Technologies, Inc. | Thermoformable multilayer moisture barrier and method of making the same |
US11208247B2 (en) | 2017-07-31 | 2021-12-28 | Société des Produits Nestlé S.A. | Packaging for solid dosage forms of melatonin with a high citric acid concentration |
US20190314318A1 (en) * | 2018-04-11 | 2019-10-17 | Robert Benson Aylor | Suppression and prevention of tumors and treatment of viruses |
DE102018112817A1 (en) | 2018-05-29 | 2019-12-05 | Klöckner Pentaplast Gmbh | Transparent polymer film with discoloration compensation |
RU198835U1 (en) * | 2019-12-30 | 2020-07-29 | Общество с ограниченной ответственностью "Научно-производственная фирма "ЛАБОВЭЙ" | Blister packaging for glucose oxidase membranes |
IT202000000787A1 (en) * | 2020-01-17 | 2021-07-17 | Sacmi Imola Sc | PROCEDURE FOR THE PRODUCTION AND FILLING OF CONTAINERS INTENDED TO CONTAIN FOOD. |
JP2023551656A (en) | 2020-11-18 | 2023-12-12 | クロックナー、ペンタプラスト、オブ、アメリカ、インコーポレイテッド | Thermoformed packaging and its forming method |
US20240182222A1 (en) * | 2022-12-05 | 2024-06-06 | Liveo Research Ag | Push through blister package with plastic lidding |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3403776A (en) * | 1967-03-21 | 1968-10-01 | Johnson & Johnson | Sterile surgical package |
US3567085A (en) * | 1968-12-02 | 1971-03-02 | James G Flores | Neck-supported pill container |
US3545604A (en) * | 1969-01-23 | 1970-12-08 | Conn Med Corp | Package |
US3913734A (en) * | 1972-08-03 | 1975-10-21 | Pharmacare Inc | Package assembly |
US3851571A (en) * | 1972-08-28 | 1974-12-03 | Nichols Prod Inc | Apparatus and method for encapsulating eggs |
FR2593152B1 (en) * | 1986-01-22 | 1988-12-23 | Adir | WATERPROOF PACKAGING IN THE FORM OF ALVEOLAR PLATES ALLOWING FOR GAS EXCHANGES BETWEEN THE ALVEOLES. |
US4923702A (en) * | 1987-07-20 | 1990-05-08 | Powell Levisky | Communion container |
DE9013901U1 (en) * | 1990-10-05 | 1990-12-20 | Hoechst Ag, 6230 Frankfurt | Pharmaceutical packaging with cap closure |
US5171593A (en) * | 1991-10-15 | 1992-12-15 | Eastern Shore Printing Corporation | Ventilated produce package, and method of making the same |
US5346069A (en) * | 1992-09-24 | 1994-09-13 | Intini Thomas D | Container |
AU669773B2 (en) * | 1993-01-22 | 1996-06-20 | Otsuka Pharmaceutical Factory, Inc. | Bicarbonate-containing powdered medicine storage container and method of stabilizing the same medicine |
JP3409543B2 (en) * | 1994-12-26 | 2003-05-26 | 味の素株式会社 | Anti-caking packaging container |
US5740938A (en) * | 1995-03-14 | 1998-04-21 | Magenta Corporation | Safety container |
US6080350A (en) * | 1995-04-19 | 2000-06-27 | Capitol Specialty Plastics, Inc. | Dessicant entrained polymer |
US6221446B1 (en) * | 1995-04-19 | 2001-04-24 | Capitol Specialty Plastics, Inc | Modified polymers having controlled transmission rates |
US6124006A (en) * | 1995-04-19 | 2000-09-26 | Capitol Specialty Plastics, Inc. | Modified polymers having controlled transmission rates |
US5911937A (en) * | 1995-04-19 | 1999-06-15 | Capitol Specialty Plastics, Inc. | Desiccant entrained polymer |
EP1000873B1 (en) * | 1995-04-19 | 2003-11-19 | CSP Technologies, Inc. | Desiccant material included in a closed container |
GB9525065D0 (en) * | 1995-12-07 | 1996-02-07 | Smithkline Beecham Plc | Packaging system |
US6173838B1 (en) * | 2000-01-31 | 2001-01-16 | Owens Illinois Closure Inc. | Child-resistant medication compact |
US6652144B2 (en) * | 2002-02-19 | 2003-11-25 | Super Chill Beverage Group Inc. | Beverage container pouch |
US7413083B2 (en) * | 2002-04-11 | 2008-08-19 | Csp Technologies, Inc. | Desiccant vial assembly for effervescent tablets |
US20030203141A1 (en) * | 2002-04-25 | 2003-10-30 | Blum John B. | Blister package |
US8110260B2 (en) * | 2007-02-02 | 2012-02-07 | Rick Merical | Containers intended for moisture-sensitive products |
US7051876B2 (en) * | 2002-08-29 | 2006-05-30 | Colbert Packaging Corporation | Pilfer-resistant packaging with criss-cross grain pattern |
GB0223798D0 (en) * | 2002-10-12 | 2002-11-20 | Cambridge Consultants | Apparatus for releasing tablets from a blister pack |
FR2848535B1 (en) * | 2002-12-17 | 2005-07-15 | D Lab | SINGLE USE PACKAGING FOR LIQUID, PASTY OR PULVERULENT PRODUCT |
RU2238894C1 (en) * | 2003-01-13 | 2004-10-27 | Плетнев Владимир Адольфович | Package |
EP1771357A1 (en) * | 2004-07-16 | 2007-04-11 | Pfizer Products Incorporated | Pharmaceutical package for simultaneously maintaining low moisture and low oxygen levels |
US20060042990A1 (en) * | 2004-08-24 | 2006-03-02 | Galuten Jerry H | Medication kit |
US20060065670A1 (en) * | 2004-09-21 | 2006-03-30 | Arjowiggins Security | Packaging device for dispensing security-protected units of product |
EP1733872A1 (en) * | 2005-06-15 | 2006-12-20 | Alcan Technology & Management Ltd. | Cold formable laminate |
WO2010068527A1 (en) * | 2008-12-10 | 2010-06-17 | Merck Sharp & Dohme Corp. | Package for oxygen-sensitive pharmaceutical products |
-
2007
- 2007-07-04 MX MX2009001041A patent/MX2009001041A/en active IP Right Grant
- 2007-07-04 KR KR20097004477A patent/KR20090036606A/en not_active Application Discontinuation
- 2007-07-04 AU AU2007280754A patent/AU2007280754B2/en not_active Ceased
- 2007-07-04 CN CNA2007800284707A patent/CN101495385A/en active Pending
- 2007-07-04 US US12/375,556 patent/US20090314664A1/en not_active Abandoned
- 2007-07-04 EP EP07765037A patent/EP2046662A1/en not_active Withdrawn
- 2007-07-04 RU RU2009107273/12A patent/RU2448026C2/en not_active IP Right Cessation
- 2007-07-04 CA CA 2659558 patent/CA2659558A1/en not_active Abandoned
- 2007-07-04 WO PCT/EP2007/005898 patent/WO2008014862A1/en active Application Filing
- 2007-07-04 BR BRPI0714619-1A patent/BRPI0714619A2/en not_active IP Right Cessation
- 2007-07-04 JP JP2009522123A patent/JP2009545343A/en active Pending
-
2009
- 2009-03-02 ZA ZA200901464A patent/ZA200901464B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2009001041A (en) | 2009-02-06 |
KR20090036606A (en) | 2009-04-14 |
BRPI0714619A2 (en) | 2013-04-30 |
RU2009107273A (en) | 2010-09-10 |
AU2007280754A1 (en) | 2008-02-07 |
WO2008014862A1 (en) | 2008-02-07 |
RU2448026C2 (en) | 2012-04-20 |
US20090314664A1 (en) | 2009-12-24 |
AU2007280754B2 (en) | 2013-02-28 |
ZA200901464B (en) | 2010-03-31 |
JP2009545343A (en) | 2009-12-24 |
EP2046662A1 (en) | 2009-04-15 |
CN101495385A (en) | 2009-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007280754B2 (en) | Packaging comprising pharmaceutical forms | |
CA2664380C (en) | Medicinal package | |
JP7241864B2 (en) | Blister Package or Packages Containing Active Ingredients, Methods of Making the Same, and Methods of Using the Same | |
US4753352A (en) | Impervious packaging in the form of a card having compartments and permitting gaseous exchange between the compartments | |
JP7118981B2 (en) | Blister pack containing active material and method of making and using same | |
US20110240511A1 (en) | Packaging for oxygen-sensitive pharmaceutical products | |
US9850051B2 (en) | Strengthened blister pack | |
CN101528179A (en) | Packaging material | |
CA2574102A1 (en) | Pharmaceutical package for simultaneously maintaining low moisture and low oxygen levels | |
US20210015776A1 (en) | Methods of stabilization of levothyroxine sodium tablets | |
AU2007344507B2 (en) | Packaging containing soft capsules | |
JP2007246092A (en) | Package | |
BR112021013269A2 (en) | BLISTER PACKAGING CONTAINING ACTIVE MATERIAL AND METHODS FOR PRODUCING AND USING THEM | |
JPH1015032A (en) | Stabilized 5-aminosalycilic acid solid pharmaceutical |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20150619 |